Related Experiment Videos
[Pharmacologic study of several alpha-adrenolytics].
Comptes Rendus Des Seances De L'Academie Des Sciences. Serie D, Sciences Naturelles
|June 30, 1980
Summary
Two novel alpha-adrenoceptor blocking agents, 170 150 and 170 153, demonstrate potent pre- and post-synaptic activity. These compounds show promise as valuable pharmacological tools for adrenoceptor research.
Area of Science:
- Pharmacology
- Adrenergic Pharmacology
- Cardiovascular Physiology
Context:
- Alpha-adrenoceptors play a critical role in regulating blood pressure and cardiac function.
- Understanding the specific actions of alpha-adrenoceptor antagonists is crucial for developing new therapeutics.
- Previous research has identified various alpha-adrenoceptor blocking agents with differing potencies and selectivities.
Purpose:
- To investigate the pharmacological properties of six novel alpha-adrenoceptor blocking agents.
- To determine the potency and efficacy of compounds 170 150 and 170 153 in preclinical models.
- To elucidate the pre- and post-synaptic activity of these agents on adrenergic signaling.
Summary:
- Compounds 170 150 and 170 153 were identified as the most potent alpha-adrenoceptor blockers among six tested agents in dogs and rats.
- At low doses, these agents reversed pressor responses to adrenaline and suppressed responses to high doses, while reducing noradrenaline-induced pressor effects.
- In dogs, 170 150 and 170 153 modulated cardiac nerve stimulation effects, including tachycardia and clonidine-induced inhibition, indicating pre- and post-synaptic alpha-adrenoceptor antagonism.
Impact:
- 170 150 and 170 153 represent potent alpha-adrenoceptor antagonists with dual pre- and post-synaptic activity.
- These compounds offer significant potential as pharmacological tools for further research into adrenergic mechanisms.
- Findings contribute to the understanding of adrenoceptor function and may inform the development of novel cardiovascular drugs.